Introduction
============

Hyperglycemia has been associated with nosocomial infections and mortality in a variety of inpatient populations^([@r01]-[@r04])^. Stress hyperglycemia is the elevation of blood glucose in the presence of acute illness. Factors contributing to hyperglycemia in critical illnesses include the release of stress hormones (e.g., epinephrine and cortisol), the use of medications such as exogenous glucocorticoids and catecholamines, and the release of inflammatory mediators in cases of sepsis or surgical trauma. All these conditions inhibit insulin release and action, thereby enhancing gluconeogenesis, inhibiting glycogen synthesis, and impairing insulin-mediated glucose uptake by peripheral tissues. Intravenous dextrose, commonly used in parenteral nutrition and antibiotic solutions, also contributes to hyperglycemia^([@r05])^.

Intensive glucose control has been shown to reduce infection rate and complications in critically ill patients in the intensive care unit (ICU) and after heart surgery^([@r06],[@r07])^. However, a recent large-scale randomized trial indicated that such glycemic control is not effective in reducing ICU mortality and that glycemic control with intensive insulin therapy increases the risk of hypoglycemia and complications arising from hypoglycemia^([@r08])^.

It is well known that hyperglycemia adversely impairs neutrophil activity, including chemotaxis, formation of reactive oxygen species and the phagocytosis of bacteria^([@r09])^. It also affects other components of the immune system, increasing lymphocyte apoptosis and suppressing the proliferation of T cells due to the decreased expression of adenosine kinase^([@r10])^. The function of immunoglobulins and complement is attenuated due to their glycosylation in the hyperglycemia environment^([@r11],[@r12])^.

The relationship between hyperglycemia and infections has rarely been studied in oncohematological patients, though it is a relevant issue in this population given their immunocompromised state and increased risk of hyperglycemia (eg. glucocorticoid use, chemotherapy induced hyperglycemia, stress induced hyperglycemia) and infections. Induction therapy for acute leukemias is performed using intense chemotherapy regimens with a high risk of neutropenic infections. In fact, neutropenic fever, an early sign of infection requiring empiric therapy, occurs almost uniformly in patients undergoing induction chemotherapy for acute leukemias, and despite aggressive treatment, progression to a more complicated infection occurs in up to 15% of these patients^([@r13])^.

There are also few studies evaluating the incidence of hyperglycemia during induction therapy of acute leukemias, and those that have been published show a range of 10% to 56% depending on the glucose level considered as hyperglycemia^([@r14]-[@r19])^.

The aim of this study was to determine the prevalence of hyperglycemia during induction therapy for acute leukemias in adult patients and to determine the effect of hyperglycemia on complicated infection, mortality and complete remission rates.

Methods
=======

A retrospective cohort analysis was performed of newly diagnosed 18- to 60-year-old acute leukemia patients \[including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) and biphenotypic acute leukemia\] treated from January 2000 through December 2009 at the Hemocentro de Pernambuco (HEMOPE), a hematology reference center in the northeast of Brazil.

Medical records were reviewed to obtain demographic information, a description of the treatment protocol, leukemia risk category, date of diagnosis, comorbidities, use of prophylactic antibiotics, duration of neutropenic fever, documented infections, remission status and death during the first 30 days of induction treatment.

Patients were excluded if they had less than two fasting glucose measurements in the first 30 days of therapy.

To determine the occurrence of hyperglycemia, all serum fasting glucose values obtained during one week prior to the beginning of chemotherapy until 30 days after therapy induction were assessed. No capillary glucose values were included in this analysis.

Hyperglycemia was defined as one or more fasting glucose values of \> 100 mg/dL during remission induction therapy. \'Early hyperglycemia\' was considered when hyperglycemia occurred one week prior to the first day of induction chemotherapy or before the development of neutropenic fever or any documented infection and \'late hyperglycemia\' when it occurred after the development of neutropenic fever or any documented infection.

Complicated infections were defined as sepsis, microbiologically documented or not, associated with hemodynamic failure requiring vasoactive drugs, the need of mechanical ventilation for respiratory failure or renal failure necessitating hemodialysis.

Complete remission was defined as a bone marrow aspirate with less than 5% blasts and restoration of normal hematopoiesis.

The frequency of glucose level measurements and glycemic control, and the use of antibiotics or antifungal therapy were defined by the attending physician.

Outcomes were evaluated for patients with hyperglycemia during the first 30 days of induction chemotherapy and compared with those of patients without evidence of hyperglycemia during the same time interval.

Primary endpoints included comparisons of the rates of complicated infections and mortality between patients who did or did not experience one or more episodes of hyperglycemia in the first 30 days of remission induction therapy.

The secondary endpoints were a comparison of these rates between patients who experienced \'early hyperglycemia\' and \'late hyperglycemia\' or hypoglycemia (defined as any glucose value \< 60 mg/dL) and comparison of number of fungal infections and complete remission rates in those with or without hyperglycemia.

Differences with regard to rates of complicated infections, mortality, fungal infections and complete remission were analyzed using a Chi-square or Fisher\'s exact test when appropriate. Comparisons were considered significant when the type I error rate was greater than 5% (p-value \< 0.05).

Multivariate logistic regression models (for complicated infections and mortality) were used to control for the effect of patient and leukemia characteristics on the association between hyperglycemia and clinical outcomes. Significant factors with a p-value \< 0.05 in univariate analysis were entered into the multivariate models.

All statistical tests were performed using the Statistical Package for Social Sciences (SPSS) using the R software package (version 2.9.0).

Results
=======

Two hundred and eighty-five patients were admitted for remission induction therapy. Five were excluded (one because there was no available information about induction therapy and four because they had less than two glucose measurements during the first 30 days). Of the 280 patients evaluated, 188 (67.1%) experienced hyperglycemia during the first 30 days of remission induction therapy, of which 134(47.8%) presented \'early hyperglycemia\' and 148 (52.8%) presented \'late hyperglycemia\'. Only 11 patients (3.9%) had previous diagnosis of diabetes mellitus. Patients had a median of five fasting glucose measurements in the first 30 days of treatment (range: 2-12).

Baseline characteristics according to hyperglycemia status are demonstrated in [Table 1](#t01){ref-type="table"}. Patients with hyperglycemia were found to be slightly older and more commonly of female gender than patients without hyperglycemia.

###### 

Patients baseline characteristics by hyperglycemia status

                                                  **Hyperglycemia**                   
  ---------------------------- ------------------ ------------------- --- ----------- ----------
  **Age (years)**                                                                     
                               18 - 29            56 (49.1)               58 (50.9)    
                               30 - 39            52 (73.2)               19 (26.8)   \< 0.001
                               40 - 60            80 (84.2)               15 (15.8)    
  **Gender**                                                                          
                               Female             103 (73.0)              38 (27.0)   0.034
  **Body mass index**                                                                 
                               18.5 - 25          101 (67.8)              48 (32.2)    
                               25.1 - 30          27 (60.0)               18 (40.0)   0.745\*
                               30.1 - 40          8 (66.7)                4 (33.3)    
                               \< 18.5            4 (5.1)                 3 (42.9)     
  **Race**                                                                            
                               White              73 (68.9)               33 (31.1)    
                               Black              5 (71.4)                2 (28.6)    0.617\*
                               Mulatto            79 (68.1)               37 (31.9)   
                               Indian             0 (0.0)                 1 (100.0)    
  **Diabetes**                                                                        
                               Yes                11 (100.0)              0 (0.0)     0.018
                               No                 176 (65.7)              92 (34.3)   
  **Comorbidity**                                                                     
                               Yes                46 (75.4)               15 (24.6)   0.120
                               No                 142 (64.8)              77 (35.2)   
  **Diagnosis**                                                                       
                               AML                109 (69.9)              47 (30.1)    
                               ALT.               76 (63.3)               44 (36.7)   0.534\*
                               Biphenotypic       3 (75.0)                1 (25.0)     
  **White blood cell count**                                                          
                               \< 30 x 10^9^/L    110 (68.3)              51 (31.7)    
                               30 x 10^9^/L       48 (63.2)               28 (36.8)   0.676
                               \> 100 x 10^9^/L   30 (69.8)               13 (30.2)    
  **Immunophenotype**                                                                 
                               AML                76 (68.5)               35 (31.5)    
                               Mature B ALL       24 (68.6)               11 (31.4)    
                               Precursor B ALL    32 (66.7)               16 (33.3)   0.806\*
                               T - ALL            12 (54.5)               10 (45.5)   
                               T precursor ALL    5 (55.6)                4 (44.4)     
                               Biphenotypic       3 (75.0)                1 (25.0)     
  **CNS involvement**                                                                 
                               Yes                13 (65.0)               7 (35.0)    0.969
                               No                 106 (65.4)              56 (34.6)   
  **AML prognosis**                                                                   
                               Favorable          6 (46.2)                7 (53.8)     
                               Intermediate       17 (65.4)               9 (34.6)    0.485
                               Unfavorable        17 (63.0)               10 (37.0)    
  **B-ALL prognosis**                                                                 
                               Low risk           10 (71.4)               4 (28.6)     
                               High risk          10 (71.4)               4 (28.6)    1.000\*
                               Very high risk     2 (66.7)                1 (33.3)     
  **T-ALL prognosis**                                                                 
                               Low risk           5 (45.5)                6 (54.5)    0.477
                               High risk          12 (60.0)               8 (40.0)    
  **Corticosteroid use**                                                              
                               Yes                79 (63.2)               46 (36.8)   0.207
                               No                 109 (70.3)              46 (29.7)   

\*p-value Fisher exact test

AML: acute myelogenous leukemia; ALL: acute lymphoblastic leukemia; CNS: central nervous system;

Eighty-two patients (29.3%) experienced complicatedinfections. The relationship between hyperglycemia during remission induction and treatment-related complicated infections during the first 30 days is shown in [Table 2](#t02){ref-type="table"}. On unadjusted univariate analysis, patients who experienced hyperglycemia had an odds ratio of 3.97 (95% confidence interval: 2.08-7.57; p-value \< 0.001) for the development of complicated infections. The risk was also increased for older patients, \'early hyperglycemia\', \'late hyperglycemia\', hypoglycemia, more than six days of febrile neutropenia and a positive blood culture. On multivariate analysis, \'late hyperglycemia\', hypoglycemia and a positive blood culture proved to be independent risk factors for the development complicated infections.

###### 

Risk of complicated infection according to risk factors

                                                 **Complicated infection**   **OR (95% CI)**                                     
  --------------------------------- ------------ --------------------------- ----------------- ------------ -------------------- ----------
  **Age (years)**                                                                                                                
                                    18 - 29      23 (20.2)                                     91 (79.8)                          
                                    30 - 39      21 (29.6)                                     50 (70.4)    1.47 (0.88 - 2.45)   0.007
                                    40 - 60      38 (40.0)                                     57 (60.0)    1.98 (1.28 - 3.08)    
  **Hyperglycemia at any time**                                                                                                  
                                    Yes          73 (38.8)                                     115 (61.2)   3.97 (2.08 - 7.57)   \< 0.001
                                    No           9 (9.8)                                       83 (90.2)                          
  **Early hyperglycemia**                                                                                                        
                                    Yes          53 (39.6)                                     81 (60.4)    2.05 (1.38 - 3.03)   \< 0.001
                                    No           28 (19.9)                                     117 (80.1)                         
  **Late hyperglycemia**                                                                                                         
                                    Yes          67 (45.3)                                     81 (54.7)    3.34 (1.96 - 5.71)   \< 0.001
                                    No           13 (13.5)                                     83 (86.5)                          
  **Hypoglycemia**                                                                                                               
                                    Yes          5 (83.3)                                      1 (16.7)     2.97 (1.98 - 4.45)   0.009\*
                                    No           77 (28.1)                                     197 (71.9)                         
  **Days of febrile neutropenia**                                                                                                
                                    \< 10 days   27 (13.0)                                     180 (87.0)                         
                                    \> 10 days   25 (58.1)                                     18 (41.9)    2.12 (1.45 - 3.11)   \< 0.001
  **Positive blood culture**                                                                                                     
                                    Yes          45 (47.4)                                     50 (52.6)    2.37 (1.66 - 3.39)   \< 0.001
                                    No           37 (20.0)                                     148 (80.0)                         

\*Fisher exact test; OR: odds ratio; CI: confidence interval.

Infection-related mortality during neutropenia was 20.7% (58 patients). Other causes of mortality during the first 30 days comprised 2.8% of the patients (three lung hemorrhage, four brain hemorrhage and one cardiogenic shock).

The odds ratio for death of patients presenting hyperglycemia was 3.55 (95% confidence interval: 1.77-7.12; p-value \< 0.001). Other variables associated with mortality on univariate analysis included age, \'early hyperglycemia\', \'late hyperglycemia\', hypoglycemia, days with febrile neutropenia and a positive blood culture ([Table 3](#t03){ref-type="table"}). On multivariate analysis the variables \'early hyperglycemia\', \'late hyperglycemia\', hypoglycemia and positive blood culture remained independent risk factors for mortality.

###### 

Risk of death according to risk factors

                                                 **Death**   **OR (95% CI)**                                     
  --------------------------------- ------------ ----------- ----------------- ------------ -------------------- ----------
  **Age (years)**                                                                                                
                                    18 - 29      19 (16.7)                     95 (83.3)                          
                                    30 - 39      17 (23.9)                     54 (76.1)    1.44 (0.80-2.57)      
                                    40 - 60      30 (31.6)                     65 (68.4)    1.89 (1.14 - 3.14)   0.041
  **Hyperglycemia at any time**                                                                                  
                                    Yes          58 (30.9)                     130 (69.1)   3.55 (1.77 - 7.12)   \< 0.001
                                    No           8 (8.7)                       84 (91.3)                          
  **Early hyperglycemia**                                                                                        
                                    Yes          45 (33.6)                     89 (66.4)    2.33 (1.47 - 3.71)   \< 0.001
                                    No           21 (14.4)                     125 (85.6)                         
  **Late hyperglycemia**                                                                                         
                                    Yes          53 (35.8)                     95 (64.2)    3.13 (1.72 - 5.67)   \< 0.001
                                    No           11 (11.5)                     85 (88.5)                          
  **Hypoglycemia**                                                                                               
                                    Yes          4 (66.7)                      2 (33.3)     2.95 (1.61 - 5.40)   0.029\*
                                    No           62 (22.6)                     212 (77.4)                         
  **Days of febrile neutropenia**                                                                                
                                    ≤ 10 days    47 (19.8)                     190 (80.2)                         
                                    \> 10 days   19 (44.2)                     24 (55.8)    2.56 (1.43 - 4.58)   \< 0.001
  **Positive blood culture**                                                                                     
                                    Yes          34 (35.8)                     61 (64.2)    2.07 (1.37 - 3.13)   0.001
                                    No           32 (17.3)                     153 (82.7)                         

\*Fisher\'s exact test; OR: odds ratio; CI: confidence interval.

Patients who experienced hyperglycemia did not exhibit significant differences in number of fungal infections (4.8% vs. 4.3%; p-value = 1.0) and complete remission rates (57.4% vs. 61.2%; p-value = 0.581).

Discussion
==========

In this retrospective cohort, hyperglycemia was frequent among adult hospitalized patients with acute leukemia submitted to a remission induction therapy. Patients presenting hyperglycemia even at a low threshold (fasting glucose \> 100 mg/dL) were at an increased risk of complicated infections and mortality, but not for fungal infections, neither for a decreased probability of complete remission.

In this study hyperglycemia was considered as at least one fasting glucose measurement \> 100 mg/dL because of the most recent guidelines for the diagnosis of diabetes mellitus / impaired glucose tolerance ^([@r20])^.

This study is consistent with two other studies in acute leukemia patients. Weiser et al. found that adult patients with ALL who experienced hyperglycemia (defined as ≥ 2 random glucose determinations ≥ 200 mg/dL) during remission induction therapy using the Hyper-Cyclophosphamide, Vincristine, Adriamycin,and Dexamethasone (CVAD) regimen had a shorter median survival (29 months vs. 88 months; p-value = 0.001) and were more likely to develop sepsis (16.5% vs. 8.0%; p-value = 0.03) or any complicated infection (sepsis, pneumonia, or fungal) (38.8% vs. 25.1%; p-value = 0.016) compared with patients without hyperglycemia^([@r19])^. Ali et al. examined the relationship between hyperglycemia and mortality during the hospitalizations of adult AML patients and found that hyperglycemia during a patient\'s hospitalization was associated with increased hospital mortality (OR: 1.38; 95% confidence interval: 1.23-1.55; p-value \< 0.001) after adjusting for covariates including disease state, treatment type and response. The rise in mortality was evident at even mild hyperglycemia levels (110-150 mg/dL). The odds of developing severe sepsis (OR: 1.24; 95% confidence interval: 1.13-1.38; p-value \< 0.001) or severe sepsis with respiratory failure (OR: 2.04; 95% confidence interval: 1.44-2.91; p-value \< 0.001) were also increased with hyperglycemia^([@r14])^.

In pediatric patients with ALL, Roberson et al. found similar outcomes with or without hyperglycemia during remission induction therapy^([@r17])^.

The results of this study demonstrated that this association of hyperglycemia and adverse outcomes persisted when the analysis was restricted to hyperglycemia occurring before neutropenic fever or documented infections. This suggests that hyperglycemia may be important early in the hospitalization of acute leukemia patients and not only during sepsis.

Derr et al. found an association between pre-neutropenia hyperglycemia and infections during the neutropenic period after bone marrow transplantation with an odds ratio of 1.11 (95% confidence interval: 1.01-1.21; p-value = 0.023) for each 10 mg/dL increase in mean glucose^([@r21])^. Another study from Japan failed to detect any effect of hyperglycemia on infection during bone marrow transplantation^([@r22])^.

Other important risk factor for mortality in the current study was the presence of hypoglycemia (\< 60 mg/dL). This finding is consistent with several studies in critically ill patients and is the most probable cause of the negative results of tight glycemic control (80-110 mg/dL) in patients with sepsis in the ICU^([@r23]-[@r25])^.

Conclusion
==========

The findings of this study are limited in part by its retrospective, single institution nature. Also, glucose levels were not sampled in a standardized fashion and there was no standard for glucose control. The diagnosis of diabetes was based on past medical history in the medical record, which may have underestimated the actual number of patients with diabetes in this cohort.

However, the results are compelling and provide a strong rationale for studying this question prospectively as well as on the issue of whether tight glycemic control improves infection and mortality rates during treatment of acute leukemia in adults.
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